The EULAR Coronavirus Vaccine (COVAX) physician-reported registry registered patients with pre-existing rheumatic and musculoskeletal diseases, who have been vaccinated against COVID-19. touchIMMUNOLOGY were delighted to speak with Prof Patrick Durez (Cliniques Universitaires Saint-Luc – Université Catholique de Louvain (UCL), Brussels, Belgium) to discuss the aims, methodology and findings of this study looking at factors associated with disease flare following COVID vaccination.
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.
The abstract ‘Factors Associated with Disease Flare Following SARS-CoV-2 Vaccination in People with Inflammatory Rheumatic and Musculoskeletal Diseases – Results from the Physician-Reported EULAR Coronavirus Vaccine (COVAX) Registry‘ (Abstract number: 2274) was presented at the ACR Convergence, November 10–14, 2022.
Questions
- What factors underlie the concern regarding disease flare in rheumatoid arthritis patients following vaccination against SARS-CoV-2? (0:18)
- What is the The European Alliance of Associations for Rheumatology (EULAR) Coronavirus Vaccine (COVAX) physician-reported registry and what are its aims? (0:58)
- What were the aims and methodology of this registry study? (2:03)
- What were the findings in terms of incidence of and risk factors for disease flare? (2:39)
- How will these data be used to inform vaccination strategies? (3:11)
Disclosures:Â Patrick Durez has nothing to disclose in relation to this video interview.
Support:Â Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the ACR Convergence 2022.
